Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP553421.RAf1L4T5dKtFYcWxU_7O-oRIU1-GkuwjvI_zgBVtjfNaI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP553421.RAf1L4T5dKtFYcWxU_7O-oRIU1-GkuwjvI_zgBVtjfNaI130_assertion type Assertion NP553421.RAf1L4T5dKtFYcWxU_7O-oRIU1-GkuwjvI_zgBVtjfNaI130_head.
- NP553421.RAf1L4T5dKtFYcWxU_7O-oRIU1-GkuwjvI_zgBVtjfNaI130_assertion wasGeneratedBy ECO_0000203 NP553421.RAf1L4T5dKtFYcWxU_7O-oRIU1-GkuwjvI_zgBVtjfNaI130_provenance.
- NP553421.RAf1L4T5dKtFYcWxU_7O-oRIU1-GkuwjvI_zgBVtjfNaI130_assertion wasDerivedFrom befree-20140225 NP553421.RAf1L4T5dKtFYcWxU_7O-oRIU1-GkuwjvI_zgBVtjfNaI130_provenance.
- NP553421.RAf1L4T5dKtFYcWxU_7O-oRIU1-GkuwjvI_zgBVtjfNaI130_assertion SIO_000772 16764754 NP553421.RAf1L4T5dKtFYcWxU_7O-oRIU1-GkuwjvI_zgBVtjfNaI130_provenance.
- NP553421.RAf1L4T5dKtFYcWxU_7O-oRIU1-GkuwjvI_zgBVtjfNaI130_assertion evidence source_evidence_literature NP553421.RAf1L4T5dKtFYcWxU_7O-oRIU1-GkuwjvI_zgBVtjfNaI130_provenance.
- NP553421.RAf1L4T5dKtFYcWxU_7O-oRIU1-GkuwjvI_zgBVtjfNaI130_assertion description "[The discovery of mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) and the positive results of the National Cancer Institute of Canada Clinical Trials Group BR.21 phase III, randomized, placebo-controlled trial of erlotinib in patients with advanced-stage non-small-cell lung cancer that had failed to respond to first- or second-line chemotherapy provides new treatment options for patients with lung cancer and new insights into the pathophysiology of this malignancy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP553421.RAf1L4T5dKtFYcWxU_7O-oRIU1-GkuwjvI_zgBVtjfNaI130_provenance.